Type 2 Diabetes Story and Treatment For a long time, dietary fat has been recognized a potentially essential modifiable risk agent for diabetes.

Slides:



Advertisements
Similar presentations
Insulin Therapy in Type 2 Diabetes: Current and Future Directions
Advertisements

Type 2 diabetes Implementing NICE guidance 2009 NICE clinical guideline 87.
NEW ORAL AGENTS IN DIABETES MANAGEMENT
Oral Hypoglycemic Drugs And Classifications
Long-term Complications of Type 2 Diabetes
Emma Harris Medicines Management Pharmacist West Suffolk Clinical Commissioning Group Educational Event 28 th January 2014 West Suffolk Hospital Education.
Type 2 Diabetes Mellitus Aetiology, Pathogenesis, History, and Treatment.
Fats as ergogens. Fat bad, Carbohydrate good Traditionally fat as an ingested fuel source during exercise has been considered taboo Conversely, the ability.
Comparing Medications for Adults With Type 2 Diabetes
Homeostatic Control of Metabolism
S_khalilzadeh. NAFLD and T2DM NAFLD is closely associated with features of the metabolic syndrome and is regarded as the hepatic manifestation of the.
Physiological role of insulin Release of insulin by beta cells –Response to elevated blood glucose level –Effects of insulin Somewhat global Major effects.
Barriers to Diabetes Control Mark E. Molitch, MD.
Chapter 36 Agents Used to Treat Hyperglycemia and Hypoglycemia.
H OW D IABETES AFFECT THE DIGESTIVE S YSTEM By: Efren Fuertes.
DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.
Control of Energy The Original Biofuels. Importance of Glucose Regulation Too little – Brain problems Too much –Osmotic water loss (cellular and systemic)
oral hypoglycemic agents
Oral Hypoglycemic Drugs
Preferred treatment options for patients with Diabetes Dr Jon Tuppen GPwSI Beechwood Surgery Brentwood.
Regulating Blood Sugar Islets of Langerhans groups of cells in the pancreas beta cells produce insulin alpha cells produce glucagon.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.
cardio protection: Focus on
Drug Development —— Metformin. Diabetes type1 vs type2.
HYPOGLYCEMIC AGENTS Rama B. Rao, M.D. Bellevue Hospital Center/NYUMC New York, N.Y.
Treatment Advances in Type 2 Diabetes Panhandle Nurse Practitioner Symposium April 11, 2015 Dr. Caleb Kim.
Oral hypoglycemic drugs
JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.
Insulin By: Zach Seabrook (Dedicated to Adam DeKoning)
DH206: Pharmacology Chapter 21: Diabetes Mellitus Lisa Mayo, RDH, BSDH.
INSULIN & ORAL HYPOGLYCEMIC AGENTS.
Oral hypoglycemic drugs
Selected Hormonal Issues Relating to Exercise and Substrate Use.
#4 Management of Diabetes Mellitus. 5 Components of Diabetes Management 5 Components of Diabetes Management Farrell, M. (2005). Textbook of Medical-Surgical.
Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.
Dr. Mansour Alzahrani. متى اكتشف داء السكري؟ داء السكري في الحضارة الهندية والصينية القديمة اسهامات علماء المسلمين في داء السكري.
 Insulin is a peptide hormone released by beta cells when glucose concentrations exceed normal levels (70–110 mg/dL).  The effects of insulin on its.
Pancreatic Hormones & Antidiabetic Drugs By S. Bohlooli, PhD Pharmacology Department Faculty of Pharmacy, Ardabil University of Medical Sciences.
Oral hypoGLYCEMICS.
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS.
Aim: What is diabetes and how is it treated?. 1) What causes Diabetes Mellitus? It is caused by an insulin deficiency (pancreas does not produce insulin)
Type 2 diabetes.
Copyright © 2015 by the American Osteopathic Association.
Glucose Homeostasis: In Health, Disease and With Treatment
GLP-1 Agonist:When to start ?
Dr. Sasan Zaeri (PharmD, PhD) Department of Pharmacology, BPUMS
Lecture on Anti Diabetic Drugs
Diabetes Mellitus Nursing Management.
Therapeutics Tutoring
Oral hypoglycemic drugs
Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)
Regulating Blood Sugar
Diabetic Disorders 4th Leading cause of deaths in the US
Drugs for Diabetes Mellitus
Luigi F. Meneghini, MD, MBA  The American Journal of Medicine 
Stuart A. Ross, MB CHB, FRACP, FRCP(C) 
המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.
Diabetic Disorders 4th Leading cause of deaths in the US
oral hypoglycemic agents
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
LESSON 8: USING MEDICINE SAFELY FOR MAXIMUM EFFECTIVENESS
Diabetes: Introduction
DIABETES MELLITUS. DIABETES MELLITUS It is a syndrome of impaired carbohydrate, protein and fat metabolism caused by either lack of insulin secretion.
Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.
Glucose-lowering medication in type 2 diabetes: overall approach.
Oral Antihyperglycemic Agents In the UKPDS, developed glycemic dominance, irrespective of the factor utilized (metformin, sulfonylureas, or insulin)
Conclusion Diabetes mellitus is actually one of the most popular chronic ailments in nearly whole countries.
Sulphonylureas and Glitazones In spite of the big number of anti-diabetic factors obtainable.
Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.
Presentation transcript:

Type 2 Diabetes Story and Treatment For a long time, dietary fat has been recognized a potentially essential modifiable risk agent for diabetes

Consuming fish, which contains high amounts of n-3 polyunsaturated fat

Social Cognitive Theory puts a multifaceted causal framework

Much of the obtainable literature in kind 2 DM

Belief in one’s efficiency to practice control

Persistent administration of GLP-1 decreases blood glucose

Sulfonylureas induces the insulin liberation in a glucose-independent pattern

In comparison, sitagliptin (the dipeptidyl peptidase-4 inhibitor) performs by steadying the DPP-4 substrates, GIP and GLP-1

Given their procedure of action, the most popular adverse impacts of sulfonylureas

Glitazones elevate nonoxidative glucose elimination, elevate triglyceride synthesis, and develop metabolism of (FFA) - free fatty acid

Though repaglinide medicine links to the sulphonylurea binding positions on β-cells of pancreas and owns an identical procedure of action

Rosiglitazone and pioglitazone which belong to Thiazolidinedione group

Alpha-glucosidase inhibitors can be utilized as an initial-line medicine in recently diagnosed kind 2 diabetes insufficiently cured with exercise and diet alone